Oncoimmunology

Article	Citations
Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer	98
Identification of pyroptosis-related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in colorectal cancer	93
Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies	75
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer	72
PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity	70
IFN-γ-induced ER stress impairs autophagy and triggers apoptosis in lung cancer cells	67
Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer	64
YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non–small-cell lung cancer	61
Ferroptosis becomes immunogenic: implications for anticancer treatments	61
Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative breast cancer	60
Exosome-mediated communication between tumor cells and tumor-associated macrophages: implications for tumor microenvironment	59
Lipid-associated macrophages in the tumor-adipose microenvironment facilitate breast cancer progression	57
YKT6 , as a potential predictor of prognosis and immunotherapy response for oral squamous cell carcinoma, is related to cell invasion, metastasis, and CD8+ T cell infiltration	54
Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study	53
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma	49
Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity	47
Integrated analyses of m 1 A regulator-mediated modification patterns in tumor microenvironment-infiltrating immune cells in colon cancer	46
TIGIT + TIM-3 + NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related	45
Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer	44
The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis	44
Trial watch: intratumoral immunotherapy	41
Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients	41
Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma	39
Gas plasma irradiation of breast cancers promotes immunogenicity, tumor reduction, and an abscopal effect in vivo	39
Tumors exploit CXCR4 hi CD62L lo aged neutrophils to facilitate metastatic spread	39

Chronic stress promotes breast carcinoma metastasis by accumulating myeloid-derived suppressor cells through activating β-adrenergic signaling	38
Association between immune-related adverse event timing and treatment outcomes	38
Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness	38
Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors	38
A multicenter characterization of hepatitis associated with immune checkpoint inhibitors	37
Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry	37
Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis	37
Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice	37
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression	36
Re-polarization of immunosuppressive macrophages to tumor-cytotoxic macrophages by repurposed metabolic drugs	36
Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer	36
CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy	35
The role of irreversible electroporation in promoting M1 macrophage polarization via regulating the HMGB1-RAGE-MAPK axis in pancreatic cancer	35
STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer	35
Tumor-intrinsic determinants of immunogenic cell death modalities	35
Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in lung adenocarcinoma	34
CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma	34
Combination of EP 4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells	34
A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer	34
Targeting stearoyl-coa desaturase enhances radiation induced ferroptosis and immunogenic cell death in esophageal squamous cell carcinoma	33
TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients	33
Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer	33
Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer	33
LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells	33
PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy	33
Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma	33
Trial watch: chemotherapy-induced immunogenic cell death in oncology	33
Neutrophil extracellular traps induce tumor metastasis through dual effects on cancer and endothelial cells	32
Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic cancer	32
Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine	32
Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma	31
Novel deep learning-based survival prediction for oral cancer by analyzing tumor-infiltrating lymphocyte profiles through CIBERSORT	31
Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer	31
Cldn-7 deficiency promotes experimental colitis and associated carcinogenesis by regulating intestinal epithelial integrity	30
M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer	30
Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion	30
PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer	30
Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis	29
Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer	29
Oral administration of Bifidobacterium breve promotes antitumor efficacy via dendritic cells-derived interleukin 12	29
PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma	29
Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity	28
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data	28
VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma	28
Characterization of immune landscape in papillary thyroid cancer reveals distinct tumor immunogenicity and implications for immunotherapy	28
Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma	28
PD-1 blockade improves the anti-tumor potency of exhausted CD3 + CD56 + NKT-like cells in patients with primary hepatocellular car	28
Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors	28
Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer	27
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma	27

PD-L2 based immune signature confers poor prognosis in HNSCC	27
Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study	27
CXCL5-mediated accumulation of mature neutrophils in lung cancer tissues impairs the differentiation program of anticancer CD8 T cells and limits the efficacy of checkpoint inhibitors	27
Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma	27
Discovery of immunogenic cell death-inducing ruthenium-based photosensitizers for anticancer photodynamic therapy	27
LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs	26
Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1	26
Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma	26
Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma	26
Combination blockade of KLRG1 and PD-1 promotes immune control of local and disseminated cancers	26
Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response	26
Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer	26
The dark side of ferroptosis in pancreatic cancer	25
TNFSF15 facilitates differentiation and polarization of macrophages toward M1 phenotype to inhibit tumor growth	25
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors	25
Single-cell profiling of infiltrating B cells and tertiary lymphoid structures in the TME of gastric adenocarcinomas	25
Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting	24
Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients	24
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure	24
Increased frequency of TIGIT + CD73-CD8 + T cells with a TOX + TCF-1low profile in patients wit	24
CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development	24
Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer	24
IgG4 induces tolerogenic M2-like macrophages and correlates with disease progression in colon cancer	24
Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538	24
Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An	24
Single-cell transcriptome analysis of CAR T-cell products reveals subpopulations, stimulation, and exhaustion signatures	24
Double-edged effects of interferons on the regulation of cancer-immunity cycle	24
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers	23
Alternol triggers immunogenic cell death via reactive oxygen species generation	23
Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma	23
Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity	23
Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response	23
Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients	23
Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner	23
Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer	23
Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients	22
IFN-γ activates the tumor cell-intrinsic STING pathway through the induction of DNA damage and cytosolic dsDNA formation	22
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression	22
Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML	22
Cross-reactivity between cancer and microbial antigens	22
Phenotypic profiling and prognostic significance of immune infiltrates in esophageal squamous cell carcinoma	22
T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer	22
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors	22
Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis	21
Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis	21
PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer	21
Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma	21
Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy	21
Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients	21
T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction	21
Early changes in the immune microenvironment of oral potentially malignant disorders reveal an unexpected association of M2 macrophages with oral cancer free survival	21
Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy	21
Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma	21
Immunological alternation in COVID-19 patients with cancer and its implications on mortality	20
DIMEimmune: Robust estimation of infiltrating lymphocytes in CNS tumors from DNA methylation profiles	20
Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils	20
PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells	20
Immunotherapy approaches for the treatment of diffuse midline gliomas	20
Immunostimulatory effects of vitamin B5 improve anticancer immunotherapy	20
Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells	20
Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer	20
MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer	20
Fibroblasts and macrophages cooperate to create a pro-tumorigenic and immune resistant environment via activation of TGF-β/IL-6 pathway in neuroblastoma	19
Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma	19
Spatial immune heterogeneity of hypoxia-induced exhausted features in high-grade glioma	19
Dissecting the heterogeneity of the microenvironment in primary and recurrent nasopharyngeal carcinomas using single-cell RNA sequencing	19
Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents	19
Loss of CD47 alters CD8+ T cell activation in vitro and immunodynamics in mice	19
Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation	19
Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer	19
T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or IL-2 production	19
An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy	19
MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy	18
PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells	18
Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy	18
A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes	18
T and NK cell abundance defines two distinct subgroups of renal cell carcinoma	18
Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors	18
CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2	18
B-cell clusters at the invasive margin associate with longer survival in early-stage oral-tongue cancer patients	18

Trial watch: Toll-like receptor ligands in cancer therapy	18
Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers	18
Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation	17
Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients	17
Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding	17
M2 macrophage-derived exosomes suppress tumor intrinsic immunogenicity to confer immunotherapy resistance	17
Anti-Ly6G binding and trafficking mediate positive neutrophil selection to unleash the anti-tumor efficacy of radiation therapy	17
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody	17
Primary tumors from mucosal barrier organs drive unique eosinophil infiltration patterns and clinical associations	17
Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies	17
A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1	17
Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinct	16
DNMT1 constrains IFNβ-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapy	16
CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment	16
CD80 expression is upregulated by TP53 activation in human cancer epithelial cells	16
Neutrophil extracellular traps promote cancer-associated inflammation and myocardial stress	16
Tumor hypoxia: an important regulator of tumor progression or a potential modulator of tumor immunogenicity?	16
Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment	16
Distinct microbial communities colonize tonsillar squamous cell carcinoma	16
Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality	16
Tumor-associated macrophages promote intratumoral conversion of conventional CD4+ T cells into regulatory T cells via PD-1 signalling	16
Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma	16
AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma	16
Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma	16
Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade	16
Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy	16
Blood microbiota diversity determines response of advanced colorectal cancer to chemotherapy combined with adoptive T cell immunotherapy	16
Prognostic value of the PrP C -ILK-IDO1 axis in the mesenchymal colorectal cancer subtype	15
Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy	15
T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival	15
Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition	15
Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA)	15
Enriched circulating and tumor-resident TGF-β+regulatory B cells in patients with melanoma promote FOXP3+Tregs	15
Influence of tumor-infiltrating immune cells on local control rate, distant metastasis, and survival in patients with soft tissue sarcoma	15
Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer	15
Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response	15
Tertiary lymphoid structures and their association to immune phenotypes and circulatory IL2 levels in pancreatic ductal adenocarcinoma	15
Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis	15
CD34 + progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rg null	15
Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060)	15
What role for AHR activation in IL4I1-mediated immunosuppression ?	14
Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers	14
A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination	14
Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance	14
Immune suppressive function of IL-1α release in the tumor microenvironment regulated by calpain 1	14
Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors	14
A novel role for an old target: CD45 for breast cancer immunotherapy	14
Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors	14
Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors	14
Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma	14
Impaired CXCL12 signaling contributes to resistance of pancreatic cancer subpopulations to T cell-mediated cytotoxicity	14
Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy	14
MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma	14
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis	14
Apoptosis-induced translocation of centromere protein F in its corresponding autoantibody production in hepatocellular carcinoma	13
Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies	13
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1	13
SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response	13
Selective depletion of polymorphonuclear myeloid derived suppressor cells in tumor beds with near infrared photoimmunotherapy enhances host immune response	13
Phased differentiation of γδ T and T CD8 tumor-infiltrating lymphocytes revealed by single-cell transcriptomics of human cancers	13
A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors	13
Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism	13
Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1	12
Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting	12
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy	12
Stimulatory and inhibitory activity of STING ligands on tumor-reactive human gamma/delta T cells	12
Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies	12
Dual role of ARPC1B in regulating the network between tumor-associated macrophages and tumor cells in glioblastoma	12
Translocation of Helicobacter hepaticus synergizes with myeloid-derived suppressor cells and contributes to breast carcinogenesis	12
CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma	12
Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles	12
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma	12
A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy	12
Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors	12
QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment	12
Integrating CD4 + T cell help for therapeutic cancer vaccination in a preclinical head and neck cancer model	12
CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model	12
Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer	12
Crizotinib and ceritinib trigger immunogenic cell death via on-target effects	12
Vasculogenic mimicry structures in melanoma support the recruitment of monocytes	12
NFATc3 inhibits hepatocarcinogenesis and HBV replication via positively regulating RIG-I-mediated interferon transcription	12
Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer	12
Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy	12
Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer	12
Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.	11
Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade	11
Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma	11
CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors	11
Combined STING levels and CD103+ T cell infiltration have significant prognostic implications for patients with cervical cancer	11
Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma	11
Prognostic role of stromal tumor-infiltrating lymphocytes in locally advanced upper tract urothelial carcinoma: A retrospective multicenter study (TSU-02 study)	11
Tumor immune infiltration estimated from gene expression profiles predicts colorectal cancer relapse	11
Altered phenotypic and metabolic characteristics of FOXP3 + CD3 + CD56 + natural killer T (NKT)	11
Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies	11
Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection	11